Treatment effects of intra‐articular triamcinolone acetonide in an equine model of recurrent joint inflammation

Background Intra‐articular triamcinolone acetonide is a widely used treatment for joint inflammation despite limited scientific evidence of its efficacy. Objectives To investigate if intra‐articular triamcinolone acetonide has sustained anti‐inflammatory effects using an equine model of repeated joi...

Full description

Saved in:
Bibliographic Details
Published in:Equine veterinary journal 2021-11, Vol.53 (6), p.1277-1286
Main Authors: Kearney, Clodagh M., Korthagen, Nicoline M., Plomp, Saskia G. M., Labberté, Margot C., Grauw, Janny C., Weeren, P. R., Brama, Pieter A. J.
Format: Article
Language:English
Subjects:
Animals
horse
Horse Diseases - drug therapy
Horses
Inflammation
Inflammation - chemically induced
Inflammation - drug therapy
Inflammation - veterinary
Injections, Intra-Articular - veterinary
joint
lipopolysaccharide
Synovial Fluid
triamcinolone acetonide
Triamcinolone Acetonide - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Intra‐articular triamcinolone acetonide is a widely used treatment for joint inflammation despite limited scientific evidence of its efficacy. Objectives To investigate if intra‐articular triamcinolone acetonide has sustained anti‐inflammatory effects using an equine model of repeated joint inflammation. Study design Randomised controlled experimental study. Method For three consecutive cycles 2 weeks apart, inflammation was induced in both middle carpal joints of eight horses by injecting 0.25 ng lipopolysaccharide (LPS). After the first LPS injection only, treatment with 12 mg triamcinolone acetonide (TA) followed in one randomly assigned joint, while the contralateral joint was treated with sterile saline (control). Clinical parameters (composite welfare scores, joint effusion, joint circumference) were recorded and synovial fluid samples were analysed for various biomarkers (total protein, WBCC; PGE2; CCL2; TNFα; MMP; GAGs; C2C; CPII) at fixed timepoints (post injection hours 0, 8, 24, 72 and 168). The effects of time and treatment on clinical and synovial fluid parameters and the presence of time–treatment interactions were tested using a linear mixed model for repeated measures with horse as a random effect, and time and treatment as fixed effects. Results The TA treated joints showed significantly higher peak synovial GAG concentrations (Difference in means 283.1875 µg/mL, 95% CI 179.8, 386.6, P 
ISSN:0425-1644
2042-3306
DOI:10.1111/evj.13396